BRPI0519317A2 - mÉtodo para marcar um vetor, composto, composiÇço radiofarmacÊutica, uso de um composto, e, mÉtodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condiÇço associada com cÂncer - Google Patents

mÉtodo para marcar um vetor, composto, composiÇço radiofarmacÊutica, uso de um composto, e, mÉtodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condiÇço associada com cÂncer

Info

Publication number
BRPI0519317A2
BRPI0519317A2 BRPI0519317-6A BRPI0519317A BRPI0519317A2 BR PI0519317 A2 BRPI0519317 A2 BR PI0519317A2 BR PI0519317 A BRPI0519317 A BR PI0519317A BR PI0519317 A2 BRPI0519317 A2 BR PI0519317A2
Authority
BR
Brazil
Prior art keywords
compound
human
animal body
methods
formula
Prior art date
Application number
BRPI0519317-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Erik Arstad
Matthias Eberhard Glaser
Original Assignee
Hammersmith Imanet Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hammersmith Imanet Ltd filed Critical Hammersmith Imanet Ltd
Publication of BRPI0519317A2 publication Critical patent/BRPI0519317A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
BRPI0519317-6A 2004-12-22 2005-12-09 mÉtodo para marcar um vetor, composto, composiÇço radiofarmacÊutica, uso de um composto, e, mÉtodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condiÇço associada com cÂncer BRPI0519317A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0428012.9A GB0428012D0 (en) 2004-12-22 2004-12-22 Radiolabelling methods
PCT/GB2005/004729 WO2006067376A2 (en) 2004-12-22 2005-12-09 Radiolabelled conjugates of rgd-containing peptides and methods for their preparation via click-chemistry

Publications (1)

Publication Number Publication Date
BRPI0519317A2 true BRPI0519317A2 (pt) 2009-01-13

Family

ID=34112991

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519317-6A BRPI0519317A2 (pt) 2004-12-22 2005-12-09 mÉtodo para marcar um vetor, composto, composiÇço radiofarmacÊutica, uso de um composto, e, mÉtodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condiÇço associada com cÂncer

Country Status (13)

Country Link
US (2) US7972588B2 (enExample)
EP (4) EP2275145A1 (enExample)
JP (2) JP5743372B2 (enExample)
KR (1) KR101314460B1 (enExample)
CN (2) CN101084020A (enExample)
AU (1) AU2005317903C1 (enExample)
BR (1) BRPI0519317A2 (enExample)
CA (2) CA2817636A1 (enExample)
GB (1) GB0428012D0 (enExample)
MX (1) MX2007007560A (enExample)
NO (1) NO341638B1 (enExample)
RU (1) RU2419627C2 (enExample)
WO (1) WO2006067376A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
US8071718B2 (en) 2004-12-22 2011-12-06 General Electric Company Selective radiolabeling of biomolecules
US8211403B2 (en) 2006-06-21 2012-07-03 Hammersmith Imanet Limited Radiolabelling methods
US20100069609A1 (en) * 2006-06-21 2010-03-18 Erik Arstad Chemical methods and apparatus
CN101528270A (zh) * 2006-08-28 2009-09-09 通用电气健康护理有限公司 基于68Ga标记的肽的放射性药物
WO2008025886A1 (en) * 2006-09-01 2008-03-06 Wallac Oy Metal chelates and chelating agents containing triazolyl subunits
EP2155259A2 (en) * 2007-05-10 2010-02-24 The Trustees of Columbia University in the City of New York Methods for diagnosing diseases and evaluating treatments therefor using pet
ES2662495T3 (es) 2007-12-20 2018-04-06 General Electric Company Radiomarcación selectiva de biomoléculas
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
GB0815831D0 (en) * 2008-09-01 2008-10-08 Imp Innovations Ltd Compounds
CA2735970A1 (en) 2008-09-05 2010-03-11 Hammersmith Imanet Limited Isatin derivatives for use as in vivo imaging agents
CN102177160B (zh) * 2008-10-10 2014-11-26 默克及其合伙人公司 作为pet放射性示踪剂的18f-标记叶酸
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
EP2210882A1 (en) * 2009-01-16 2010-07-28 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Synthesis of new protected azahistidine, their processes and their use in synthesises
US8435488B2 (en) * 2009-02-27 2013-05-07 Genentech, Inc. Methods and compositions for protein labelling
US8722014B2 (en) * 2009-05-01 2014-05-13 Washington University 1 H-[1, 2, 3] triazole substituted amino acids and uses thereof
GB0914543D0 (en) * 2009-08-20 2009-09-30 Ge Healthcare Ltd Radioiodination method
EP2498826A1 (en) * 2009-11-11 2012-09-19 NeuroSearch AS Labelled pyrrolyl-oxadiazolyl-diazabicyclononane derivatives and their use in diagnostic methods
GB0921573D0 (en) * 2009-12-10 2010-01-27 Ge Healthcare Ltd Iodine radiolabelling method
GB0922304D0 (en) 2009-12-22 2010-02-03 Ge Healthcare Ltd Radioiodinated compounds
US20120269725A1 (en) * 2009-12-23 2012-10-25 Janine Baranowska-Kortylewicz Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer
US9517279B2 (en) * 2010-04-14 2016-12-13 The Mclean Hospital Corporation 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof
EP2575897A4 (en) * 2010-06-01 2016-06-01 Advanced Proteome Therapeutics Inc CROSSLINKING OF PROTEINS AND OTHER ENTITIES THROUGH ALPHA-HALO-ACETOPHENONES CONJUGATES, BENZYL HALIDES, QUINONES
CN103221398B (zh) * 2010-07-23 2016-03-23 特拉华大学 用于快速构建放射性核素标记探针的四嗪-反式环辛烯连接反应
GB201014023D0 (en) * 2010-08-20 2010-10-06 Ucl Business Plc Process for producing bioconjugates and products thereof
WO2012074840A2 (en) 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
GB201019824D0 (en) 2010-11-23 2011-01-05 Ge Healthcare Ltd Radioiodination method
GB201021369D0 (en) 2010-12-16 2011-01-26 Ge Healthcare Ltd Radioiodinated fatty acids
GB201021517D0 (en) 2010-12-20 2011-02-02 Ge Healthcare Ltd Radioiodinated guanidines
WO2012087912A1 (en) 2010-12-22 2012-06-28 Ge Healthcare Limited Her2 binding peptides labelled with a 18f - containing organosilicon compound
MX2013007365A (es) 2010-12-22 2013-09-26 Ge Healthcare Ltd Péptidos de enlace her2 etiquetados con fluoruro de aluminio- [18] combinados mediante nota.
EP2680889B1 (en) 2011-03-01 2019-06-19 GE Healthcare Limited Radiolabelled octreotate analogues as pet tracers
US20120251448A1 (en) * 2011-03-03 2012-10-04 Hefti Franz F Compounds for Use in the Detection of Neurodegenerative Diseases
US9023318B2 (en) * 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
WO2013048832A1 (en) 2011-09-29 2013-04-04 Ge Healthcare Limited 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells
WO2013048811A1 (en) 2011-09-30 2013-04-04 Ge Healthcare Limited Imaging and radiotherapy methods for tumour stem cells
US20140335019A1 (en) * 2011-12-02 2014-11-13 The Regents Of The University Of Michigan Compositions and methods for the treatment and analysis of neurological disorders
GB201121911D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Radiofluorination method
US20150017093A1 (en) * 2012-02-03 2015-01-15 Aarhus Universitet Radiolabeled bile acids and bile acid derivatives
EP2657213A1 (en) * 2012-04-24 2013-10-30 Institut National de la Santé et de la Recherche Medicale Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors
US20140065070A1 (en) * 2012-08-28 2014-03-06 Mcmaster University Methods of preparing triazole-containing radioiodinated compounds
US20160137639A1 (en) * 2012-10-26 2016-05-19 Japan Tobacco Inc. Triazole-isoxazole compound and medical use thereof
US20150023877A1 (en) * 2013-07-18 2015-01-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of parkinsons disease diagnosis and monitoring treatment
ES2700348T3 (es) * 2014-01-05 2019-02-15 Univ Washington Trazadores radioetiquetados para poli (ADP-ribosa) polimerasa-1 (PARP-1), métodos y usos para estos
US20160022846A1 (en) * 2014-07-22 2016-01-28 Ge Healthcare Limited Iodine radiolabelling method
PT3310816T (pt) * 2015-06-19 2020-10-19 Eisai R&D Man Co Ltd Imunoglobulinas conjugadas cys80
WO2017023999A1 (en) * 2015-08-03 2017-02-09 Emory University Methylsulfonamide derivatives and uses related thereto
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
CN112638415B (zh) * 2018-07-26 2024-07-02 大有华夏生物医药集团有限公司 用于成像的组合物和方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4913891A (en) * 1986-04-17 1990-04-03 The United States Of America As Represented By The United States Department Of Energy Positron emitter labeled enzyme inhibitors
HK1056164B (en) 2000-03-24 2013-06-21 Euro-Celtique S.A. Aryl-substituted pyrazole, triazole and tetrazole, and their uses
US6350360B1 (en) 2000-04-07 2002-02-26 Sandia Coroporation Method of fabricating a 3-dimensional tool master
CN1230441C (zh) * 2000-04-12 2005-12-07 安盛药业有限公司 结合整联蛋白的肽衍生物
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
IL159310A0 (en) 2001-07-10 2004-06-01 Amersham Health As Peptide-based compounds
EP2226316B1 (en) 2002-05-30 2016-01-13 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
AU2003297859A1 (en) * 2002-12-13 2004-07-09 The Trustees Of Columbia University In The City Of New York Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry
KR101171397B1 (ko) * 2003-04-17 2012-08-07 더 스크립스 리서치 인스티튜트 진핵 유전자 코드의 확장
CA2527877A1 (en) * 2003-06-18 2005-01-13 The Scripps Research Institute Unnatural reactive amino acid genetic code additions
NO20033115D0 (no) 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
EP1799273A2 (en) * 2004-10-07 2007-06-27 Koninklijke Philips Electronics N.V. Use of the staudinger ligation in imaging and therapy end kits for imaging and therapy
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods

Also Published As

Publication number Publication date
MX2007007560A (es) 2007-11-21
AU2005317903C1 (en) 2012-05-10
WO2006067376A3 (en) 2007-07-26
CA2589136C (en) 2015-10-06
GB0428012D0 (en) 2005-01-26
KR20070091626A (ko) 2007-09-11
US20090311177A1 (en) 2009-12-17
US7972588B2 (en) 2011-07-05
KR101314460B1 (ko) 2013-10-10
AU2005317903B2 (en) 2011-12-01
RU2007122804A (ru) 2009-01-27
AU2005317903B8 (en) 2012-01-19
AU2005317903A1 (en) 2006-06-29
EP2275145A1 (en) 2011-01-19
US20110236311A1 (en) 2011-09-29
CN105012972A (zh) 2015-11-04
RU2419627C2 (ru) 2011-05-27
WO2006067376A2 (en) 2006-06-29
EP1830890A2 (en) 2007-09-12
CA2817636A1 (en) 2006-06-29
EP2258403A1 (en) 2010-12-08
JP2008528445A (ja) 2008-07-31
NO341638B1 (no) 2017-12-18
JP2012254998A (ja) 2012-12-27
CN101084020A (zh) 2007-12-05
JP5743372B2 (ja) 2015-07-01
US8679455B2 (en) 2014-03-25
EP2266629B1 (en) 2015-12-09
EP2266629A1 (en) 2010-12-29
NO20073157L (no) 2007-06-20
CA2589136A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
BRPI0519317A2 (pt) mÉtodo para marcar um vetor, composto, composiÇço radiofarmacÊutica, uso de um composto, e, mÉtodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condiÇço associada com cÂncer
WO2007148089A3 (en) Radiolabelling methods
Müller et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
WO2015073746A3 (en) 18f labeling of proteins using sortases
bin Othman et al. Re-assessing gallium-67 as a therapeutic radionuclide
MY150757A (en) Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins
MY163136A (en) Peptide radiotracer compositions
ATE411819T1 (de) Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel
Maleki et al. Structural modifications of amino acid sequences of radiolabeled peptides for targeted tumor imaging
Ikotun et al. Investigation of a vitamin B12 conjugate as a PET imaging probe
WO2009134405A3 (en) Substrate based pet imaging agents
Maschauer et al. In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot study
BRPI0409101A (pt) método para produzir um complexo de gálio radiomarcado
WO2009018175A3 (en) Cyclic azapeptides as integrin markers
WO2009134382A3 (en) Cyclopeptides containing rgd mimetics as imaging markers for integrins
Métivier et al. Preclinical evaluation of a 64Cu-based theranostic approach in a murine model of multiple myeloma
Miao et al. Therapeutic efficacy of a 177Lu-labeled DOTA conjugated α-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model
Kanellopoulos et al. Key-protease inhibition regimens promote tumor targeting of neurotensin radioligands
BRPI0518636A2 (pt) kits nço-radioativo liofilizado e de multi-doses, processo para a preparaÇço de méltiplas doses de paciente unitÁrias do radiofarmacÊutico tetrofosmina-99mtc, composiÇço radiofarmacÊutica estabilizada, e, dose de paciente unitÁria do radiofarmacÊutico tetrofosmina-99mtc
RAMLI et al. Preclinical study of 177Lu-DOTA-trastuzumab: A potential radiopharmaceutical for therapy of breast cancer positive HER-2
Maisonial et al. Synthesis, radioiodination and in vivo screening of novel potent iodinated and fluorinated radiotracers as melanoma imaging and therapeutic probes
Szücs et al. Investigation of the effect on the albumin binding moiety for the pharmacokinetic properties of 68ga-, 205/206bi-, and 177Lu-Labeled NAPamide-Based radiopharmaceuticals
Tehrani et al. Evaluation of 99m Tc-MccJ25 peptide analog in mice bearing B16F10 melanoma tumor as a diagnostic radiotracer
Eryilmaz et al. Detailed chemistry studies of 225Actinium labeled radiopharmaceuticals
WO2019204432A3 (en) Fluorine-18 labeled compositions and their use in imaging of biological tissue

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 11, 8O C/C 13 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.